New spray chemotherapy trial targets Hard-to-Treat ovarian cancer
NCT ID NCT07273396
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a method called PIPAC, where the chemotherapy drug paclitaxel is turned into a pressurized spray and delivered directly into the abdomen. It is for women with ovarian cancer that has come back and no longer responds to platinum-based chemotherapy. The trial has two phases: first to find the safest dose, then to see how well it controls the disease. About 53 women will take part, receiving the treatment every six weeks for up to nine cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
paclitaxel
What this could lead to
If successful, this could offer a new treatment option for women with ovarian cancer that has spread to the abdomen and no longer responds to standard chemotherapy.
What could go wrong
This is an early-phase trial with only 53 participants, so results may not apply broadly. The chemotherapy is given as a gas under pressure, which carries risks like toxicity or pain, and the cancer may still progress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••